Shots:

• NCCN and Pfizer have issued an open RFP that develop and validate enduring approaches to improve the safe- effective- and efficient adoption of biosimilars in oncology
• The RFP supports approaches to improve the processes related to biosimilar adoption in oncology. Letters of Intent are welcome from academic or community centers- patient advocacy groups and HCPs organizations in the US and are due on Sept 09- 2020
• The NCCN ORP will boost up the discovery that improves the lives of people with cancer and supports preclinical- translational- clinical research and quality improvement projects in oncology

  Ref: PRNewswire | Image: NCCN